These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 14534332)
1. Pharmacologic approaches to correcting the basic defect in cystic fibrosis. Lukacs GL; Durie PR N Engl J Med; 2003 Oct; 349(15):1401-4. PubMed ID: 14534332 [No Abstract] [Full Text] [Related]
2. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. Wilschanski M; Yahav Y; Yaacov Y; Blau H; Bentur L; Rivlin J; Aviram M; Bdolah-Abram T; Bebok Z; Shushi L; Kerem B; Kerem E N Engl J Med; 2003 Oct; 349(15):1433-41. PubMed ID: 14534336 [TBL] [Abstract][Full Text] [Related]
3. Pharmacological induction of CFTR function in patients with cystic fibrosis: mutation-specific therapy. Kerem E Pediatr Pulmonol; 2005 Sep; 40(3):183-96. PubMed ID: 15880796 [TBL] [Abstract][Full Text] [Related]
4. Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin. Linde L; Boelz S; Nissim-Rafinia M; Oren YS; Wilschanski M; Yaacov Y; Virgilis D; Neu-Yilik G; Kulozik AE; Kerem E; Kerem B J Clin Invest; 2007 Mar; 117(3):683-92. PubMed ID: 17290305 [TBL] [Abstract][Full Text] [Related]
5. Limited premature termination codon suppression by read-through agents in cystic fibrosis intestinal organoids. Zomer-van Ommen DD; Vijftigschild LA; Kruisselbrink E; Vonk AM; Dekkers JF; Janssens HM; de Winter-de Groot KM; van der Ent CK; Beekman JM J Cyst Fibros; 2016 Mar; 15(2):158-62. PubMed ID: 26255232 [TBL] [Abstract][Full Text] [Related]
6. Use of protein repair therapy in the treatment of cystic fibrosis. Rubenstein RC; Zeitlin PL Curr Opin Pediatr; 1998 Jun; 10(3):250-5. PubMed ID: 9716885 [TBL] [Abstract][Full Text] [Related]
7. Pharmacologic therapy for stop mutations: how much CFTR activity is enough? Kerem E Curr Opin Pulm Med; 2004 Nov; 10(6):547-52. PubMed ID: 15510065 [TBL] [Abstract][Full Text] [Related]
8. Gentamicin in pharmacogenetic approach to treatment of cystic fibrosis. Hamilton JW Lancet; 2001 Dec; 358(9298):2014-6. PubMed ID: 11755605 [No Abstract] [Full Text] [Related]
9. Tobramycin is a suppressor of premature termination codons. Altamura N; Castaldo R; Finotti A; Breveglieri G; Salvatori F; Zuccato C; Gambari R; Panin GC; Borgatti M J Cyst Fibros; 2013 Dec; 12(6):806-11. PubMed ID: 23540394 [TBL] [Abstract][Full Text] [Related]
10. [From the laboratory to the clinic: CFTR and the therapeutic options for cystic fibrosis]. Mayol J; Alvarez de Arcaya Vicente A; Arbeo Escolar AM; Peña Soria MJ; Alvarez Fernández-Represa J An Med Interna; 2000 Feb; 17(2):92-8. PubMed ID: 10829466 [TBL] [Abstract][Full Text] [Related]
11. Mutation specific therapy in CF. Kerem E Paediatr Respir Rev; 2006; 7 Suppl 1():S166-9. PubMed ID: 16798551 [TBL] [Abstract][Full Text] [Related]
17. [From gene to disease; from defective chloride ion transport to cystic fibrosis]. Scheffer H; van den Ouweland AM; Veeze HJ Ned Tijdschr Geneeskd; 2001 Apr; 145(14):686-7. PubMed ID: 11530706 [TBL] [Abstract][Full Text] [Related]